Online first
Letter to the Editors
Published online: 2025-01-30
Neurotoxicity of levodopa/carbidopa intestinal gel preparations can cause polyneuropathy in Parkinson’s Disease patients
1
DOI: 10.5603/pjnns.104394
Pubmed: 39883019
Abstract
Not available
Keywords: levodopa/carbidopa intestinal gelpolyneuropathyParkinson’s Diseasehyperhomocysteinaemiavitamin de iciency
References
- Havránková P, Roth J, Čapek V, et al. Acute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson's Disease. Neurol Neurochir Pol. 2024; 58(6): 586–592.
- Hsu RT, Bumanlag F, Mehta AK, et al. Homocysteine and Peripheral Neuropathy. Journal of Neurology and Experimental Neuroscience. 2020; 6(2): 58–61.
- Hoogeveen EK, Kostense PJ, Valk GDE, et al. Hyperhomocysteinaemia is not related to risk of distal somatic polyneuropathy: The Hoorn Study. Journal of Internal Medicine. 1999; 246(6): 561–566.
- Parein G, Bollens B. Nitrous oxide-induced polyneuropathy, pancytopenia and pulmonary embolism: a case report. J Med Case Rep. 2023; 17(1): 350.
- Neveu J, Perelman S, Suisse G, et al. Severe hyperhomocysteinemia and peripheral neuropathy as side effects of nitrous oxide in two patients with sickle cell disease. Arch Pediatr. 2019; 26(7): 419–421.
- Rispoli V, Simioni V, Capone JG, et al. Peripheral neuropathy in 30 duodopa patients with vitamins B supplementation. Acta Neurol Scand. 2017; 136(6): 660–667.
